Merck wins Hi-Tech case
Executive Summary
The Federal Circuit U.S. Court of Appeals on March 30 rejected Hi-Tech's novel argument that Merck's anti-glaucoma drug patent was not entitled to patent term extension because the patent had a terminal disclaimer. Such a disclaimer specifies that a drug is not "patentably distinct" from an earlier patent; Hi-Tech argued that the patent covering Trusopt (dorzolamide) and Cosopt (dorzolamide/timolol) would thus expire on the date of the previous patent (1"The Pink Sheet" Feb. 5, 2007, p. 8)...
You may also be interested in...
Patent Extension Arguments In Merck v. Hi-Tech Case Have Broad Implications
Generic manufacturer Hi-Tech Pharmacal is pursuing a unusual challenge to Merck's patent for the anti-glaucoma drug dorzolamide
Zydus Cadila Testing Three-Dose COVID-19 Vaccine
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Six Questions For Sun Pharma MD Shanghvi
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: